2016 Opioid Prescribing Guideline

Archived Content: This Page Is No Longer Being Updated

This page is archived for historical purposes and is no longer being maintained or updated.

Please see Process for Updating the Opioid Prescribing Guideline for the most up-to-date information.

Workgroup Charge

The Opioid Guideline Workgroup – 2016 was charged with:

  1. Reviewing the quality of the clinical and contextual evidence reviews.
  2. Reviewing each of the recommendation statements and accompanying rationale
  3. Considering for each recommendation:
    1. The quality of the evidence supporting the recommendation (the accuracy of the evidence quality rating; i.e., evidence “type”);
    2. The balance of benefits and risks associated with the recommendation (the degree to which the benefit of issuing the recommendation outweighs the harms);
    3. The values and preferences of providers and patients related to the recommendation (the degree to which there is variability or uncertainty in values and preferences);
    4. The cost feasibility of the recommendation (the degree to which implementation is feasible for health systems and patients financially); and
    5. The category designation of the recommendation (whether category A or category B is justified). Category A recommendations apply to all patients; Category B recommendations require individual decision making where different choices will be appropriate for different patients so that providers must help patients arrive at a decision consistent with patient values and preferences and specific clinical situations.
    6. Workgroup members will be provided with the Proposed 2016 Guideline for Prescribing for Opioids for Chronic Pain and other supporting materials to assist with items #1-3.
    7. Provide a summary of the workgroup’s observations associated with items #1-3 above of the Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain, including points of agreement and disagreement.

Report: “Observations Presented to the National Center for Injury Prevention and Control’s Board of Scientific Counselors” – Opioid Guideline Workgroup [PDF 429 KB]


Christina A. Porucznik, Ph.D., M.S.P.H.
Associate Professor
Department of Family and Preventive Medicine
University of Utah

Designated Federal Official

Amy B. Peeples, M.P.A.
Deputy Director
National Center for Injury Prevention and Control
Centers for Disease Control and Prevention

Workgroup Membership

Anne Burns, R.Ph.
Vice President, Professional Affairs
American Pharmacists Association

Penney Cowan
Executive Director
American Chronic Pain Association

Traci Green, Ph.D.
Deputy Director
Boston Medical Center Injury Prevention Center
Boston School of Medicine
Associate Professor of Emergency Medicine
  and Epidemiology
The Warren Alpert School of Medicine of Brown University
Rhode Island Hospital

Mitchell Katz, M.D.
Los Angeles County Health

Erin Krebs, M.D., M.P.H.
Associate Professor of Medicine
Women’s Health Medical Director
Minneapolis VA Health Care System
University of Minnesota

Chinazo Cunningham, M.D., M.S.
Associate Chief
Division of General Internal Medicine
Albert Einstein College of Medicine
Montefiore Medical Center

Katherine Galluzzi, D.O., C.M.D.,F.A.C.O.F.P.
Professor and Chair
Department of Geriatrics
Director, Comprehensive Care at
   Philadelphia College of Osteopathic Medicine

Gregory Terman, M.D., Ph.D.
Department of Anesthesiology and Pain Medicine
   and the Graduate Program in Neurobiology Behavior
University of Washington

Mark Wallace, M.D.
Professor of Clinical Anesthesiology
Chair Division of Pain Medicine
University of California, San Diego Medical Center